Carregant...

Targeting the Ras pathway in pediatric hematologic malignancies

PURPOSE: Ras pathway mutations are one of the most common type of alterations in pediatric hematologic malignancies and are frequently associated with adverse outcomes. Despite ongoing efforts to use targeted treatments, there remain no food and drug administration (FDA) approved medications specifi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Opin Pediatr
Autors principals: Pikman, Yana, Stieglitz, Elliot
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7880552/
https://ncbi.nlm.nih.gov/pubmed/33394740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOP.0000000000000981
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!